<SEC-DOCUMENT>0001493152-19-000728.txt : 20190117
<SEC-HEADER>0001493152-19-000728.hdr.sgml : 20190117
<ACCEPTANCE-DATETIME>20190117085819
ACCESSION NUMBER:		0001493152-19-000728
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190117
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190117
DATE AS OF CHANGE:		20190117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		19530122

	BUSINESS ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported): January 17, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>MICROBOT
MEDICAL INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-19871</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3078125</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
        or other jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
        incorporation)</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission
        </B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
        Number)</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS
        Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25
        Recreation Park Drive, Unit 108</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hingham,
        Massachusetts 02043</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
    of Principal Executive Offices) (Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant&rsquo;s
telephone number, including area code: (781) 875-3605</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Former
Name or Former Address, if Changed Since Last Report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
&sect;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 7.01</B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
    FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: windowtext">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: windowtext">On
January 17, 2019, Microbot Medical Inc. (the &ldquo;Company&rdquo;) issued a press release announcing that it </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstrated
an activated Self-Cleaning Shunt (SCS<SUP>TM</SUP>) during recent one-on-one investor and analyst meetings in San Francisco, which
took place during the same week as the JP Morgan Healthcare conference. The Company&rsquo;s SCS<SUP>TM</SUP> was activated from
a working prototype of its customized headset that is intended to be used periodically by either the patient or the healthcare
provider for the operation of the SCS<SUP>TM</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this Item 7.01 and in Exhibit 99.1 of Item 9.01 is being furnished pursuant to Item 7.01 and shall not be deemed
to be &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this
Item 7.01 or Exhibit 99.1 of Item 9.01.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    9.01</B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
    Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.65in; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 0.1in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated January 17, 2019 </FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 63pt; text-align: justify; text-indent: -63pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICROBOT
    MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    <FONT STYLE="font-variant: small-caps">Harel Gadot</FONT></I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Chairman</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
January 17, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_1.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Showcases a Working Prototype of its Self-Cleaning Shunt</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hingham,
MA &ndash; January 17, 2019 &ndash; Microbot Medical Inc. (Nasdaq CM: MBOT) demonstrated an activated Self-Cleaning Shunt (SCS<SUP>TM</SUP>)
during recent one-on-one investor and analyst meetings in San Francisco, which took place during the same week as the JP Morgan
Healthcare conference. The Company&rsquo;s SCS<SUP>TM</SUP> was activated from a working prototype of its customized headset that
is intended to be used periodically by either the patient or the healthcare provider for the operation of the SCS<SUP>TM</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Following
our recent successful lab and pre-clinical testing of the SCS<SUP>TM</SUP>, coupled with the progress we made with the development
of our SCS<SUP>TM</SUP> device, we are pleased to see the enormous interest and positive feedback from the professional community
as we start exposing them to the device&rdquo;, commented Harel Gadot, President, Chief Executive Officer and Chairman of Microbot.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_2.jpg" ALT="" STYLE="height: 163; width: 160">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
small-group demonstrations followed a live demonstration of the headset at the International Society for Hydrocephalus and Cerebrospinal
Fluid Disorders (ISHCFD) annual meeting held in Bologna, Italy in October 2018. The ISHCFD was also the first time that, in front
of leading global neurologists, the Company&rsquo;s pre-clinical study results were presented by Professor Pat McAllister, Department
of Neurosurgery, Washington University School of Medicine, St. Louis. Dr. McAllister&rsquo;s presentation was titled <B>&ldquo;Biocompatibility
of the Novel Microbot Medical SCS<SUP>TM</SUP> Shunt Catheter</B>&rdquo; and was part of the Company&rsquo;s participation at
the annual meeting. It highlighted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In-vitro
                                         study performed at Wayne State University, which supports the SCS<SUP>TM</SUP>&rsquo;s
                                         potential as a viable technology for preventing occlusion in shunts used to treat hydrocephalus.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In-vivo
                                         animal study performed at Washington University School of Medicine in St. Louis, which
                                         supports the safety profile of the Company&rsquo;s SCS<SUP>TM</SUP> as a CSF catheter.
                                         </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s innovative SCS<SUP>TM</SUP> is designed to prevent obstruction in the cerebrospinal fluid (CSF) catheters implanted
in the ventricle of the brain of patients who suffer from hydrocephalus or Normal Pressure Hydrocephalus (NPH).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&trade;,
which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes
in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot&rsquo;s
current technological platforms, ViRob<SUP>TM</SUP>, TipCAT<SUP>TM</SUP> and CardioSert<SUP>TM</SUP>, are comprised of three highly
advanced technologies, from which the Company is currently developing its first product candidate: the Self Cleaning Shunt, or
SCS<SUP>TM</SUP>, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and focusing on the development
of a Multi Generation Pipeline Portfolio (MGPP) utilizing all technologies. Further information about Microbot Medical is available
at http://www.microbotmedical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ViRob<SUP>TM</SUP> technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the
body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels,
the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages
as well as the ability to remain within the human body for prolonged time. To learn more about ViRob<SUP>TM</SUP> please visit
http://www.microbotmedical.com/technology/virob/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TipCAT<SUP>TM
</SUP>is a transformational self-propelled, flexible, and semi-disposable locomotive device providing see &amp; treat capabilities
within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly
suitable to navigate and crawl through natural &amp; artificial tubular lumens, applying the minimal necessary pressure to achieve
the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT<SUP>TM</SUP>,
visit http://www.microbotmedical.com/technology/tipcat/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CardioSert<SUP>TM
</SUP>technology contemplates a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal
surgery. The CardioSert<SUP>TM</SUP> technology features unique steering and stiffness control capabilities, and it was originally
developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during
percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as
peripheral intervention, neurosurgery and urology. CardioSert<SUP>TM</SUP> was part of a technological incubator supported by
the Israel Innovation Authorities (formerly known as the Office of the Chief Scientist, or OCS), and its device has successfully
completed pre-clinical testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;expects&rdquo; and &ldquo;estimates&rdquo;) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development
and/or commercialization of potential products, the outcome of its studies to evaluate the SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many uncertainties that affect the businesses of Microbot Medical
Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.&rsquo;s filings with the Securities
and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contacts: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Polyviou</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVC
Group</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mpolyviou@evcgroup.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">732-933-2754</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">###</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_1.jpg
<TEXT>
begin 644 ex99-1_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 .$# 2(  A$! Q$!_\0
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M$D$$#M715Y)X#_Y'"/\ Z]W_ )BO6Z "BBB@ HHHH ***S-6UVRT8QBZ9@9
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)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_2.jpg
<TEXT>
begin 644 ex99-1_2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %O 6D# 2(  A$! Q$!_\0
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M!756/PZ\&Z=C[-X:TT$=#+ )#^;9KIZ* *D&E:=:_P#'OI]I%_N0*O\ (5:
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MT/4/$FL6^E:9 TUU<-A1V [DGL!U)KZY\">!=.\"Z(MG;*);N0 W5T1S*_\
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M-I<"ZLK>Y7I-$L@_$9J:@ I*6B@!**** "FT44 >:_'.3;\/D7^_?PC]&/\
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M?A8;GB=0/N%!M_EG]:]S^#GC>?Q9I=[;7,(CDLV!7:<C![?Y]: /+/C:[/\
M$?48S_#! J_3:"/US7 2RB2R+],C->T?'+P])=^+=#N;=!G48S:$G@;T;(S^
M#'\J\GUWPWJ>@+%9WL4>Z5<QO$^]2 >3ZC\J /K/P3<F\\":#<'J]A#G_OD"
MM^N,^&>HV$W@G2=/M[Z"XNK.U6.9(R05(]B <?A79T %%%% !24M% #****
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MOBJ8[IS]:^T? >JV^L>"=*N;9'2-(%A*OU!0;?Z9_&@#I***,T %-IV:;F@
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M\.0:^2@P89'(->O_  6\7_9[IO#EY)^[G.ZW+'I)Z?CT^H% 'KVEZ9:Z%:2
MSY+MF6:8A<GM["K5]96NIV$]E=QB6TN(S%(G9E(KC?B-ID]\^G2MN>Q0L)(A
MT$AQ@D?3(JSX(OVM[<:5<,=HR;?=_".Z_P!10!\U^-_"UQX1\376DS[G6/\
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MF4<$XX4>P_7)- '5BEI*6@!U%%&* &XI*?BC% #Z*** &FDIU(10 RFTZDH
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M%!'ZUE?\(GHD<@EBT>R$@Z-Y()'YUTWE"E""@#B-6\."<E@N<US%WX-AF^_
M"?7%>O&('M4#6<1_A% 'B,O@#GY%X]#5K3OAX3.,PCKUKV+[##_<%2QVZQ]%
M H R=%TA-,M5B48QUK8"U(%Q2T ,V4NVG48H 3%&*?BC% #,48I]-H ****
M"D-+10 PTVGFF$4 --)3C330 R2-98V1U#1L,,K#((]"*^9/B[\/QX9U4:EI
MT3#2KMCL Y\I^Z'^8]N.U?3AK,UO1K3Q!H]SI5^FZ"X7!(ZJ>S#W!YH ^)*O
MZ-JUQHFIPWMLV'C.<>M:WC#PK?>%M<N;"[3YD.1(H^5T/1A['].E<UB@#Z=T
M/4+76]+@U"T(,<@Y&?NGN#6NJ=Z\&^'/BQM U0VMU(?L%P,..NT]F_SVKWH2
M J&4@@C@CO0!2U73+;6=+N-/NUW0SQ[6]1Z$>XZU\YZGH-UI&K7.F7&[S8C_
M  ]'7L1^'-?2DLRJI;.,=2:\E\>:OINJ7D?]GQ27-W$-K3Q<)QT&>^/:@#S9
M+7<TB$.70\A1DD?G6EINGW$\Z16L&QW. ?O.?IZ?AS5JWT34]5N8VE"I@]47
M!_.O9/!/A3[ $F=?FQU/4T ;?PU\$+X>@%_=\WSKA5SGR@>N3ZFO115*V7RX
MP*NKTH 6G48I0* $ IX% %. H  *=1BEH 2EHIU !BC%%% !BFXIU% #:*=3
M: "G4VG4 %-IU% !BC%%% !1110 4444 %%%% #:*=3: "BBB@!*0BG44 1$
M4TBIB*:10!$:C-2D4PB@#DO'?@NV\9:/Y1VQW\&3;3GL>ZM_LG].M?,.L^&K
MO2-2EL[VWDMYXSAD8?J/;WZ5]D$5FZKH6F:Y$(M3L(;I5^Z9%Y7Z'J* /D*W
ML6&-J<UZEX3\2W-EH_V6^M[FXCA&()8USG_9)/IZUZM;?#CPO;R;TTI6/82N
MT@'X$UHGPU:<#REV#@+C@4 >17,6K>)#MG4PVI_Y81G@_P"\>_\ *KMGX*4
M JH_"O5%T*W3[J!?I4JZ6J]!0!QFF>%H+=@=@)]<5U=K9"(# Q5Y;7;_  U.
ML.* &(N*L**%CJ4+0 T"G 4[%+0 @%+BC%.H ;13J* #%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 VBBB@ HHHH *3%+10
M W%,*U+10!#Y=*(ZEHH :%Q2X%+10 TK2;*?10 S92A:=BC% "8I:,4[% #:
M=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
)%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
